Pyrrolidines
Levetiracetam, a pyrrolidine derivative, is a newer
antiseizure drug that’s chemically unrelated to previously available
antiepilep-tic drugs. It’s used as adjunctive therapy to treat certain types of
partial and myoclonic seizures.
Levetiracetam is administered orally or I.V. Oral
administration re-sults in rapid and full absorption with a 100%
bioavailability. Peak concentrations occur in about 1 hour. Levetiracetam isn’t
exten-sively metabolized; any metabolites that are produced aren’t ac-tive. The
major metabolic pathway is enzymatic hydrolysis, and metabolism doesn’t depend
on any hepatic cytochrome P450 isoenzymes. Levetiracetam is eliminated by renal
excretion. The half-life is about 8 hours and is unaffected by dose, route of
ad-ministration, or repeated administration.
The precise mechanism of action isn’t known. The
drug’s antiepileptic effect doesn’t appear to involve known mechanisms relating
to inhibitory and excitatory neurotransmission.
Levetiracetam has several indications for us,
including:
·
adjunctive therapy for epilepsy in adults and children older than age 4
·
adjunctive treatment for myoclonic seizures in adults and chil-dren
older than age 12
·
adjunctive treatment for primary generalized tonic-clonic seizures in
adults and children older than age 6.
Levetiracetam has no known major drug interactions.
(See Ad-verse reactions to levetiracetam.)
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.